UPDATE: Burrill Initiates Rexahn Pharmaceuticals at Market Outperform on Promising Oncology Drug

Burrill initiated coverage on Rexahn Pharmaceuticals RNN with a Market Outperform rating and a $1 price target. Burrill commented, "We believe that Rexahn's promising pipeline in oncology and CNS disorders is undervalued, and a successful result in any of the ongoing trials may offer significant upside for investors with high risk tolerance. … Rexahn's leading oncology drug, Archexin, is a first-in-class anti-sense drug targeting the Akt-1 gene, with an orphan designation for glioblastoma, pancreatic, stomach, ovarian, and renal cancers. Rexahn has completed a Phase 2a trial in pancreatic cancer, with promising survival data in a subset of evaluable patients." Rexahn Pharmaceuticals closed at $0.29 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorInitiationIntraday UpdateAnalyst RatingsBurrill
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!